LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

LLY

1,070.32

-0.45%↓

JNJ

205.85

-0.71%↓

ABBV

228.65

+0.42%↑

UNH

324.98

-0.04%↓

AZN

92.05

+0.56%↑

Home・Aandelen Lijst・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Gesloten

SectorGezondheidszorg

38.23 -1.62

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

38.21

Max

39.54

Belangrijke statistieken
By Trading Economics
Inkomsten	11M 51M
Verkoop	39M 239M
K/W Sectorgemiddelde	12.259 78.892
EPS	1.08
Winstmarge	21.242
Werknemers	268
EBITDA	14M 73M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+18.37% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	551M 2.2B
Vorige openingsprijs	39.85
Vorige sluitingsprijs	38.23

Nieuwssentiment

By Acuity

50%

156 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

29.8 / N/A Steun & Weerstand

Harmony Biosciences Holdings Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 dec 2025, 15:21 UTC

Winsten

Correction to Home Depot Outlook Headline on Dec. 9

23 dec 2025, 23:54 UTC

Marktinformatie

Gold Climbs Above $4,500/oz for First Time Amid Rising Geopolitical Tensions -- Market Talk

23 dec 2025, 23:40 UTC

Marktinformatie

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

23 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

23 dec 2025, 21:21 UTC

Acquisities, Fusies, Overnames

St Barbara to Use Deposit Toward A$370 Million Subscription to Buy 50% of Simberi Unit

23 dec 2025, 21:20 UTC

Acquisities, Fusies, Overnames

St Barbara to Hold Deposit in Escrow

23 dec 2025, 21:20 UTC

Acquisities, Fusies, Overnames

St Barbara: Deposit Represents Progress on Lingbao's Strategic Investment in Simberi Mine

23 dec 2025, 21:19 UTC

Acquisities, Fusies, Overnames

St Barbara Receives A$32 Million Deposit From Lingbao Gold

23 dec 2025, 21:13 UTC

Acquisities, Fusies, Overnames

ServiceNow Bets on Cybersecurity to Boost Growth -- Analysis

23 dec 2025, 20:16 UTC

Marktinformatie

Oil Futures Settle Higher on Geopolitical Tensions -- Market Talk

23 dec 2025, 20:14 UTC

Marktinformatie

U.S. Natural Gas Soars on Colder Weather Outlook -- Market Talk

23 dec 2025, 19:13 UTC

Winsten

Acquisities, Fusies, Overnames

Mergers and Acquisitions Soared This Year. 2026 Could Be Even Bigger. -- Barrons.com

23 dec 2025, 18:58 UTC

Marktinformatie

Gold Has Another Record-Setting Day -- Market Talk

23 dec 2025, 18:32 UTC

Marktinformatie

U.S. Oil Rig Count Rises By 3 to 409 -- Market Talk

23 dec 2025, 17:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Tech, Media & Telecom Roundup: Market Talk

23 dec 2025, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

23 dec 2025, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

23 dec 2025, 17:09 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Armis Seen as Good Fit for ServiceNow in $7.8B Deal -- Market Talk

23 dec 2025, 16:21 UTC

Marktinformatie

Monthly Canadian GDP Points to Flat Activity So Far for 4Q -- Market Talk

23 dec 2025, 16:16 UTC

Marktinformatie

Recent 'Disorderly' Yen Falls Could Justify Intervention -- Market Talk

23 dec 2025, 16:15 UTC

Marktinformatie

Precious Metals Pare Gains -- Market Talk

23 dec 2025, 16:03 UTC

Acquisities, Fusies, Overnames

Erste Group Bank: Closing Expected Around Mid-January

23 dec 2025, 16:03 UTC

Acquisities, Fusies, Overnames

Erste Group Bank Also Obtained Regulatory Approvals for 50% Stake in Santander Towarzystwo Funduszy Inwestycyjnych

23 dec 2025, 16:02 UTC

Acquisities, Fusies, Overnames

Erste Group Bank Obtained Regulatory Approvals by Polish Regulator KNF for Acquisition of Roughly 49% Controlling Stake in Santander Bank Polska

23 dec 2025, 16:01 UTC

Acquisities, Fusies, Overnames

Erste Group Bank Receives Green Light for Acquisition in Poland

23 dec 2025, 15:42 UTC

Acquisities, Fusies, Overnames

Telefonica: Agreement is For Sale of Telefonica Tech Business in Colombia, Mexico, Chile

23 dec 2025, 15:42 UTC

Acquisities, Fusies, Overnames

Telefonica Doesn't Set Out Financial Details of Divestment

23 dec 2025, 15:41 UTC

Acquisities, Fusies, Overnames

Telefonica: Deal Will Allow Focus on Core Markets

23 dec 2025, 15:40 UTC

Acquisities, Fusies, Overnames

Telefonica To Sell Telefonica Tech South American Business to Hiberus

23 dec 2025, 15:19 UTC

Marktinformatie

Fixed-Income Traders Misread Underlying Strength of Canada Economy -- Market Talk

Peer Vergelijking

Prijswijziging

Harmony Biosciences Holdings Inc Prognose

Koersdoel

By TipRanks

18.37% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 46 USD 18.37%

Hoogste 62 USD

Laagste 32 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Harmony Biosciences Holdings Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Harmony Biosciences Holdings Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

29.8 / N/ASteun & Weerstand

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

156 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.